Remimazolam is used for sedation during medical procedures and for inducing anesthesia before surgery, helping patients stay calm and comfortable during these medical interventions.[2] Anerem is currently approved and in use across 29 indications[4].[1]
Anerem is one of 498 small molecule programs targeting Glioma. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
1931 competitors in COVID-19
Anerem
COVID-19 Vaccine
Nexavar
Tricor
Benadryl
Nitrostat
Orap
Calcium
Biological Data
Olokizumab
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Oct 6, 2020
BYFAVO
NDA NDA212295
Sources
Details